Loading data for BLTE — first visit, this takes a few seconds.

알림

Belite Bio Inc (BLTE)

NasdaqCM: BLTE · 실시간 가격 · USD

151.72

-5.29 (-3.37%)

종가 기준: Aug 28, 2026, 8:00 PM

151.72

+0.00%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-3.37% (1D)

데이터 없음

매수호가	112.02
시가총액	6.11B
매출 (ttm)	n/a
순이익 (ttm)	-102.36M
	-1.23
	-2.64
	n/a
	70.85
P/B (ttm)	7.87
P/S (ttm)	n/a
실적 발표일	Nov 9, 2026

매도호가	154.6
거래량	164,772
평균 거래량 (20일)	197,663
시가	156.75
전일 종가	157.01
일중 범위	151.15 - 156.75
52주 범위	62.18 - 200.00
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

BLTE 소개

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The c...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Apr 29, 2022

직원 수 41

상장 거래소 NasdaqCM

티커 BLTE

웹사이트 https://www.belitebio.com

전체 기업 정보

재무 실적

2025년 Belite Bio Inc의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -77.61M로, 114.73% 증가했습니다.

재무제표

어닝 서프라이즈

Belite Bio Inc가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.7 예상치 상회 0.08, 및 -40.00% 전년 대비 감소.

다음 실적 발표

Belite Bio Inc의 실적 발표 예정일은 Nov 9, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · Simply Wall St.

Belite Bio (BLTE) Could Be 21% Undervalued On FDA Priority Review News

Belite Bio (BLTE) is back in focus after the FDA accepted its New Drug Application for tinlarebant with Priority Review, a key regulatory step that accompanies the company’s latest quarterly earnings ...

2주 전 · Simply Wall St.

Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run

Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to a less straightforward picture of how much is alre...

2주 전 · GuruFocus.com

Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...

Belite Bio Inc (BLTE) reports robust progress with FDA NDA acceptance and a $780 million cash runway, despite widening losses and delayed GA trial interim analysis.

2주 전 · MarketBeat

Belite Bio Q2 Earnings Call Highlights

Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the applicati...

2주 전 · Zacks

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

2 페이지 중 1

Belite Bio Inc (BLTE)